Scarica l'app Stockscreener
1.035
1.43%
-0.015
Dopo l'orario di chiusura:
1.04
0.005
+0.48%
Precedente Chiudi:
$1.05
Aprire:
$1.06
Volume 24 ore:
402.81K
Relative Volume:
0.83
Capitalizzazione di mercato:
$64.09M
Reddito:
$248.00K
Utile/perdita netta:
$-113.22M
Rapporto P/E:
-0.562
EPS:
-1.8416
Flusso di cassa netto:
$-98.81M
1 W Prestazione:
-4.17%
1M Prestazione:
-10.78%
6M Prestazione:
-23.33%
1 anno Prestazione:
-31.00%
Intervallo 1D:
$1.03
$1.065
Intervallo di 1 settimana:
$1.03
$1.12
Portata 52W:
$1.02
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Nome
Pliant Therapeutics Inc
Settore
Industria
Telefono
650-481-6770
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.035 | 66.88M | 248.00K | -113.22M | -98.81M | -1.8416 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Ripresa | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Downgrade | Needham | Buy → Hold |
| 2025-03-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Downgrade | Citigroup | Buy → Neutral |
| 2025-02-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-05-18 | Iniziato | Canaccord Genuity | Buy |
| 2023-04-13 | Iniziato | Robert W. Baird | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-07 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Outperform |
| 2022-05-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-03 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-20 | Iniziato | BTIG Research | Buy |
| 2021-04-05 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Cowen | Outperform |
| 2020-06-29 | Iniziato | Needham | Buy |
| 2020-06-29 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie
Pliant Therapeutics Names David Raben CMO - Voice of Healthcare
Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer - TradingView
Pliant Therapeutics names David Raben as chief medical officer - Investing.com
Dr. David Raben appointed chief medical officer at Pliant Therapeutics - Traders Union
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - Yahoo! Finance Canada
Pliant Therapeutics Stock Price Forecast. Should You Buy PLRX? - StockInvest.us
Pliant Therapeutics, Inc.(NasdaqGS: PLRX) dropped from S&P Global BMI Index - marketscreener.com
Pliant Therapeutics (PLRX) Slips 1.77% to $1.11, Testing Support Near $1.05Social Sentiment - siam.in
Price to earnings forward of Pliant Therapeutics, Inc. – DUS:9PT - TradingView
FDA Grants Fast Track to PLN-101095 Plus Pembrolizumab in Solid Tumors - Targeted Oncology
Pliant (PLRX) Watch: Finishes 1.74% Up at $1.17 at the Close; Technical View: the $1.11 to $1.23 Range Remains in Focus in the Available RecordUnusual Put Volume - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Why is Pliant Therapeutics stock climbing today? - Investing.com
Why is Pliant Therapeutics stock climbing today? By Investing.com - Investing.com India
Pliant Therapeutics (PLRX) Gains FDA Fast Track for PLN-101095 A - GuruFocus
Pliant Therapeutics receives FDA fast track for cancer drug By Investing.com - Investing.com Canada
Pliant Therapeutics receives FDA fast track for cancer drug - Investing.com
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - The Manila Times
Pliant Therapeutics Receives FDA Fast Track Designation for - GlobeNewswire
J.P. Morgan Maintains Pliant Therapeutics(PLRX.US) With Sell Rating - Moomoo
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics (PLRX) Advances Clinical Program Amidst Chal - GuruFocus
Monaco Asset Management SAM Purchases Shares of 1,938,747 Pliant Therapeutics, Inc. $PLRX - MarketBeat
Pliant Therapeutics Inc (FRA:9PT) Stock Price, Trades & News - GuruFocus
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support ZoneValue Stock Ideas - vinanet.vn
Pliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to Sell - MarketBeat
Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital - Stock Titan
Pliant Therapeutics (PLRX): Citadel entities, Kenneth Griffin report 3.5% holding - Stock Titan
Price performance - Yahoo Finance Australia
CCORF Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - Moomoo
RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
PLRX (Pliant Therapeutics) 12-1 Month Momentum % : -30.79% (As of Aug. 17, 2026) - GuruFocus
Pliant Therapeutics cuts Q2 loss to $22.4M on lower costs - scanx.trade
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Pliant Therapeutics (PLRX) halves quarterly loss and reports $159.6M in cash reserves - Stock Titan
BRIEF-Pliant Therapeutics Q2 Net Income USD -22.371 Million - TradingView
Pliant Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Fibrosis Pipeline AdvancesNext Quarter Guidance - dars.gov.et
Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pliant Therapeutics Inc (PLRX) Stock News Today - TradingKey
Pliant Therapeutics, Inc. expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (PLRX) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest DeclineLinear Regression - vinanet.vn
Pliant Therapeutics (PLRX) Edges Higher Amid Tight Trading Range — Key Levels in FocusVolatility Stop - dars.gov.et
Pliant Therapeutics Inc (PLRX) Income Statement - TradingKey
Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pliant Therapeutics Inc (PLRX) Cash Flow - TradingKey
Pliant Therapeutics Inc (PLRX) Balance Sheet - TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pliant Therapeutics Inc Azioni (PLRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cheung Lily | Chief Human Resource Officer |
Jan 20 '26 |
Sale |
1.28 |
7,534 |
9,644 |
44,847 |
| Coulie Bernard | President and CEO |
Jan 20 '26 |
Sale |
1.28 |
89,375 |
114,400 |
505,601 |
| Kuo Minnie | Chief Operating Officer |
Jan 20 '26 |
Sale |
1.28 |
6,917 |
8,854 |
37,806 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):